



STALLERGENES
Allergen Vaccines Worldwide
PRESS RELEASE

Paris, France

14 April 2005

Significant increase in 2005 1st quarter sales: + 21%

€ millions	2005 Q 1	2004 Q1	% growth
France	17.70	13.99	+ 27%
Subsidiaries ⁽¹⁾	9.66	8.54	+ 13%
Distributors	2.94	2.58	+ 14%
Total	30.30	25.11	+ 21%

⁽¹⁾ Germany, Belgium, Italy, Spain and Portugal

Stallergènes Group reported a sustained growth in 2005 1st quarter sales of 21%, primarily relating to a very strong growth in sales in France of 27% in continuation of 2004 end of year activity.

Subsidiaries' sales rose 13%, notably benefiting from the end of the 10% sales price regulatory discount in Germany. 2005 1st quarter sales do not incorporate sales of the Group's Spanish subsidiary IPI, which was acquired on 9 March 2005, and whose sales will be consolidated from 1 April 2005.

Distributors' sales improved by 14%, with all countries reporting regular growth.

This very good start of year, which was widely expected, enables the Group to confirm its 2005 forecast of double digit organic sales growth and continuing profitability growth.

About STALLERGENES

Stallergènes Group is today the world's leading pharmaceutical laboratory specialising in allergen immunotherapy, both in terms of number of patients treated (N^o1) and sales (N^o2). In its 40 years of existence, Stallergènes has established itself as a dynamic player, frequently as an innovator, in the battle to prevent and cure allergies, rhinitis and asthma in particular.

Stallergènes devotes over 10% of its sales to its Research and Development activities.

Stallergènes' development is focused on the French market and on international markets through its subsidiaries based in Germany, Italy, Spain, Portugal and Belgium, and its distributors based in Eastern Europe, North Africa and elsewhere.

Shares of the Group's parent company, Stallergènes SA, are listed on the Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN Code: FR0000065674

Reuters Code: GEN.PA

Bloomberg Code: GEN.FP

All Group financial information is available on our web site at:

www.stallergenes.com